EA200870569A1 - Соединения и способы модуляции fxr - Google Patents

Соединения и способы модуляции fxr

Info

Publication number
EA200870569A1
EA200870569A1 EA200870569A EA200870569A EA200870569A1 EA 200870569 A1 EA200870569 A1 EA 200870569A1 EA 200870569 A EA200870569 A EA 200870569A EA 200870569 A EA200870569 A EA 200870569A EA 200870569 A1 EA200870569 A1 EA 200870569A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
connections
fxr modulation
compounds
fxr
Prior art date
Application number
EA200870569A
Other languages
English (en)
Other versions
EA014720B1 (ru
Inventor
Майкл Грегори Белл
Роберт Энтони Доти
Мэттью Скотт Даулинг
Майкл Джеймс Генин
Питер Амброз Ландер
Тяньвэй Ма
Натан Брайан Мэнтло
Джейсон Мэттью Очоада
Линдсэй Скотт Стельзер
Райан Эдвард Ститс
Алан М. Варшавски
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200870569A1 publication Critical patent/EA200870569A1/ru
Publication of EA014720B1 publication Critical patent/EA014720B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

В изобретении предложены соединения формулыгде переменные являются такими, как определено в данном описании, а также фармацевтические композиции, содержащие указанные соединения, и способы их применения. Предложенные согласно изобретению соединения и композиции полезны в лечении дислипидемии и родственных заболеваний.
EA200870569A 2006-05-24 2007-05-22 Соединения и способы модуляции fxr EA014720B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80810406P 2006-05-24 2006-05-24
US87000106P 2006-12-14 2006-12-14
PCT/US2007/069416 WO2007140174A2 (en) 2006-05-24 2007-05-22 Compounds and methods for modulating fxr

Publications (2)

Publication Number Publication Date
EA200870569A1 true EA200870569A1 (ru) 2009-06-30
EA014720B1 EA014720B1 (ru) 2011-02-28

Family

ID=38626336

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870569A EA014720B1 (ru) 2006-05-24 2007-05-22 Соединения и способы модуляции fxr

Country Status (16)

Country Link
US (1) US8106077B2 (ru)
EP (1) EP2029558B1 (ru)
JP (1) JP5225984B2 (ru)
AR (1) AR061101A1 (ru)
AT (1) ATE460403T1 (ru)
AU (1) AU2007267692B2 (ru)
BR (1) BRPI0711875A2 (ru)
CA (1) CA2651373A1 (ru)
CL (1) CL2007001451A1 (ru)
DE (1) DE602007005256D1 (ru)
EA (1) EA014720B1 (ru)
ES (1) ES2340221T3 (ru)
MX (1) MX2008014959A (ru)
PE (1) PE20080259A1 (ru)
TW (1) TW200812982A (ru)
WO (1) WO2007140174A2 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2581504C2 (ru) * 2010-11-09 2016-04-20 Ф. Хоффманн-Ля Рош Аг Производные триазола и их применение при неврологических заболеваниях
RU2582337C2 (ru) * 2010-11-09 2016-04-27 Ф.Хоффманн-Ля Рош Аг Производные триазола в качестве лигандов рецепторов гамк

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) * 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2011507909A (ja) 2007-12-20 2011-03-10 エンビボ ファーマシューティカルズ インコーポレイテッド 四置換ベンゼン
WO2009102761A1 (en) 2008-02-12 2009-08-20 Bristol-Myers Squibb Company 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
KR101372104B1 (ko) * 2008-09-25 2014-03-07 에프. 호프만-라 로슈 아게 이상지질혈증 및 관련 질병에 대한 ｆｘｒ 조절제로서의 2,3-치환된 인다졸 또는 4,5,6,7-테트라하이드로-인다졸
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8252826B2 (en) 2010-03-24 2012-08-28 Hoffmann-La Roche Inc. Cyclopentyl- and cycloheptylpyrazoles
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
ES2564257T3 (es) 2010-09-28 2016-03-21 Bristol-Myers Squibb Company Nuevos análogos de piperazina con grupos heteroarilo sustituidos como antivirales de amplio espectro de la gripe
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
IL253437A0 (en) * 2011-07-13 2017-09-28 Gilead Sciences Inc New compounds modulate fxr (nr1h4) activity and bind
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US9475797B2 (en) * 2012-06-26 2016-10-25 Saniona A/S Phenyl triazole derivative and its use for modulating the GABAA receptor complex
RS61540B1 (sr) 2013-09-11 2021-04-29 Inst Nat Sante Rech Med Postupci i farmaceutske kompozicije za tretiranje infekcije hepatitis b virusa
JP2017505770A (ja) 2014-01-24 2017-02-23 シンアフィックス ビー．ブイ． （ヘテロ）アリール１，３−双極子化合物と（ヘテロ）シクロアルキンとの環化付加のためのプロセス
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
MA41094A (fr) * 2014-12-02 2017-10-10 Lilly Co Eli Procédés de traitement de troubles rénaux
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
JP7306791B2 (ja) 2015-02-06 2023-07-11 インターセプト ファーマシューティカルズ， インコーポレイテッド 併用療法のための医薬組成物
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CR20170456A (es) 2015-04-07 2018-06-13 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapias combinadas
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
MX2019009908A (es) 2017-02-21 2019-10-14 Genfit Combinacion de un agonista de ppar con un agonista de fxr.
PL3600309T3 (pl) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Skojarzenia terapeutyczne do leczenia chorób wątroby
EP3600293A1 (en) 2017-03-30 2020-02-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
RU2741306C1 (ru) * 2017-04-12 2021-01-25 Ил Дон Фармасьютикал Ко., Лтд. Производные изоксазола в качестве агонистов ядерных рецепторов и их применение
CN111511731B (zh) 2017-11-01 2023-05-23 百时美施贵宝公司 作为法尼醇x受体调节剂的烯烃化合物
EP3704107B1 (en) 2017-11-01 2023-04-12 Bristol-Myers Squibb Company Multicyclic compounds as farnesoid x receptor modulators
SG11202003830SA (en) 2017-11-01 2020-05-28 Bristol Myers Squibb Co Alkene spirocyclic compounds as farnesoid x receptor modulators
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
CA3124702A1 (en) 2019-01-15 2020-07-23 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
WO2020243590A1 (en) 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
AU2020312735A1 (en) 2019-07-18 2021-12-16 Enyo Pharma Method for decreasing adverse-effects of interferon
CN110878052B (zh) * 2019-12-11 2021-05-07 山东大学 一种含有fxr激动剂的化合物及其制备方法和应用
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists to treat hepatitis d virus infection
EP4126858A1 (en) 2020-03-26 2023-02-08 Richter Gedeon Nyrt. Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
AU2022209084A1 (en) 2021-01-14 2023-08-10 Centre Leon Bérard Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
ATE381542T1 (de) * 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
AU2003290700A1 (en) * 2002-11-22 2004-06-18 Smithkline Beecham Corporation Farnesoid x receptor agonists
BRPI0417947A (pt) * 2003-12-22 2007-04-17 Lilly Co Eli composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2581504C2 (ru) * 2010-11-09 2016-04-20 Ф. Хоффманн-Ля Рош Аг Производные триазола и их применение при неврологических заболеваниях
RU2582337C2 (ru) * 2010-11-09 2016-04-27 Ф.Хоффманн-Ля Рош Аг Производные триазола в качестве лигандов рецепторов гамк

Also Published As

Publication number Publication date
MX2008014959A (es) 2008-12-09
WO2007140174A3 (en) 2008-03-20
AU2007267692A1 (en) 2007-12-06
ATE460403T1 (de) 2010-03-15
EP2029558A2 (en) 2009-03-04
JP2009538333A (ja) 2009-11-05
BRPI0711875A2 (pt) 2012-01-10
CL2007001451A1 (es) 2008-01-11
PE20080259A1 (es) 2008-04-10
TW200812982A (en) 2008-03-16
US8106077B2 (en) 2012-01-31
EA014720B1 (ru) 2011-02-28
JP5225984B2 (ja) 2013-07-03
US20090093524A1 (en) 2009-04-09
CA2651373A1 (en) 2007-12-06
WO2007140174A2 (en) 2007-12-06
DE602007005256D1 (de) 2010-04-22
ES2340221T3 (es) 2010-05-31
AU2007267692B2 (en) 2012-06-14
AR061101A1 (es) 2008-08-06
EP2029558B1 (en) 2010-03-10

Similar Documents

Publication Publication Date Title
EA200870569A1 (ru) Соединения и способы модуляции fxr
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
EA201070247A1 (ru) Ингибиторы протеасом
EA200870570A1 (ru) Агонисты fxr
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA201691142A1 (ru) Ингибиторы мек и способы их применения
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA200900959A1 (ru) Ингибиторы мек
ATE447559T1 (de) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
EA200801565A1 (ru) Производные пиримидиниларилмочевины в качестве ингибиторов фактора роста фибробластов ( fgf-фактора )
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
EA200700225A1 (ru) Аналоги тетрапептида
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200802050A1 (ru) Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ TJ RU